Treat-and-Extend Versus Pro re nata Regimens of Ranibizumab and Aflibercept in Neovascular Age-Related Macular Degeneration: A Comparative Study from Routine Clinical Practice-Reference-Cited by-同舟云学术

Treat-and-Extend Versus Pro re nata Regimens of Ranibizumab and Aflibercept in Neovascular Age-Related Macular Degeneration: A Comparative Study from Routine Clinical Practice

Published:2024-07-08 Issue:9 Volume:13 Page:2343-2355
ISSN:2193-8245
Container-title:Ophthalmology and Therapy
language:en
Short-container-title:Ophthalmol Ther

Author:

Debourdeau Eloi^ORCID,Beylerian Helene,Nguyen Vuong,Barthelmes Daniel,Gillies Mark,Gabrielle Pierre Henry,Vujosevic Stela,Otoole Louise,Puzo Martin,Creuzot-Garcher Catherine,Wolff Benjamin,Daien Vincent, ,Cohn A.,Marsh Bacchus,Jaross N.,Barry R.,McLean I.,Guillaumie T.,Miri A.,Gabrielle P.,Tick S.,Field A.,Wickremasinghe S.,Dayajeewa C.,Wells J.,Dunlop A.,Young S.,Mimoun G.,Guymer R.,Carnota P.,Gallego-Pinazo R.,Layana A. García,Saenz-de-Viteri M.,Ferrier R.,Chow L.,Steiner H.,Amini A.,Chen J.,Saha N.,Windle P.,Gillies M.,Hunt A.,Beaumont P.,Louw Z.,Luckie A.,Lake S.,Qatarneh D.,Sararols L.,Suarez J.,Berdoukas P.,Viola F.,Milner R. Montejano,Arruabarrena C.,Ascaso F.,Murillo A. Boned,Díaz M.,Rivases G. Perez,Castiella S. Alforja,Casaroli-Marano R.,Figueras-Roca M.,Zarranz-Ventura J.,Moreno S. Gismero,Escobar A. González,Gutiérrez JMoreno,Escobar J.,Lavid F.,Muñoz P. Catalán,Sempere M. Tena,Ricci F.,Iturralde L. Broc,Sánchez S. Gómez,Garay-Aramburu G.,Sanz N. Munoz,Calvo P.,Sanchez J.,Alonso E. Almazan,Zamora M. Garcia,Ciancas E.,Gonzalez-Lopez J.,Lorenzo D.,Acebes M.,Aparicio-Sanchis S.,Hortelano A. Fernández,Sánchez A. Piñero,García García L.,Martínez E. Salinas,Gesto A. Campo,Núñez M. Rodriguez,Manning L.,Invernizzi A.,Castelnovo L.,Michel G.,Wolff B.,Perks M.,Arnold J.,Cass H.,OToole L.,Tang K.,Chung C.,Daien V.,Banerjee G.,Morgan M.,Game J.,Thompson C.,Chalasani R.,Chilov M.,Fung A.,Nothling S.,Chong R.,Fraser-Bell S.,Younan C.,Louis D.,Lockie P.,Wong J.,Hinchcliffe P.,Barthelmes D.,De Durana Santa Coloma E. Diaz,Garay-Aramburu G.,Vujosevic S.,Morros H. Brosa,Harper A.,ODay J.,Hooper C.,Cid Maria Jose Rodríguez

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40123-024-00983-2.pdf

Reference24 articles.

1. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–31.

2. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116(1):57-65.e5.

3. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537–48.

4. Busbee BG, Ho AC, Brown DM, Heier JS, Suñer IJ, Li Z, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013;120(5):1046–56.

5. IVAN Study Investigators, Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119(7):1399–411.